J&J Lung Cancer Ambitions Possibly Boosted By New Rybrevant Data
New Rybrevant Data Could Boost J&J Lung Cancer Ambitions
Improvements in PFS compared to chemotherapy may help broaden Rybrevant’s indication in EGFR-mutated non-small cell lunger cancer. Investors await data from a head-to-head trial testing it versus AstraZeneca’s Tagrisso.